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Abstract
Background: Elevated plasma fibrinogen levels are a well known finding in acute infectious diseases, acute stroke
and myocardial infarction. However its role in the cerebrospinal fluid (CSF) of acute and chronic central (CNS) and
peripheral nervous system (PNS) diseases is unclear.
Findings: We analyzed CSF and plasma fibrinogen levels together with routine parameters in patients with
multiple sclerosis (MS), acute inflammatory diseases of the CNS (bacterial and viral meningoencephalitis, BM and
VM) and PNS (Guillain-Barré syndrome; GBS), as well as in non-inflammatory neurological controls (OND) in a total
of 103 patients. Additionally, MS patients underwent cerebral MRI scans at time of lumbar puncture.
CSF and plasma fibrinogen levels were significantly lower in patients with MS and OND patients as compared to
patients with BM, VM and GBS. There was a close correlation between fibrinogen levels and albumin quotient (rho
= 0.769, p < 0.001) which strongly suggests passive transfer of fibrinogen through the blood-CSF-barrier during
acute inflammation. Hence, in MS, the prototype of chronic neuroinflammation, CSF fibrinogen levels were not
elevated and could not be correlated to clinical and neuroradiological outcome parameters.
Conclusions: Although previous work has shown clear evidence of the involvement of fibrinogen in MS
pathogenesis, this is not accompanied by increased fibrinogen in the CSF compartment.
Keywords: blood-CSF barrier (BCSFB), cerebrospinal fluid (CSF), central nervous system (CNS), fibrinogen,
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Background
Fibrinogen is a soluble 340 kDa dimeric glycoprotein
that is synthesized in the liver, secreted into the plasma
and able to signal via a number of receptors expressed
on cells of the hematopoietic, immune and nervous sys-
tems [1,2]. Apart from its pivotal role in thrombogen-
esis, inflammation, immune responses and
atherogenesis, it is also a prominent acute-phase reac-
tant. Transiently elevated plasma fibrinogen levels have
been described in acute infectious diseases, in acute
stroke and myocardial infarction; chronically raised
plasma fibrinogen levels have been associated with an
increased risk for cardiovascular diseases [3]. Whilst the
significance of plasma fibrinogen is well established, the
determination of fibrinogen in cerebrospinal fluid (CSF)
has so far been restricted to descriptions of elevated
fibrinogen degradation products in the CSF of patients
with subarachnoid haemorrhage, traumatic brain injury
and Guillain-Barré syndrome (GBS) [4-6].
Accumulations of fibrinogen and its degradation pro-
ducts have been demonstrated in the central nervous
system (CNS) tissue of stroke, bacterial meningitis (BM),
HIV-encephalitis, Alzheimer’s disease and multiple
sclerosis (MS) patients [7]. In MS, the leakage of fibrino-
gen into the CNS was found to result in microglial acti-
vation and plaque formation [8]. In experimental
allergic encephalomyelitis (EAE), an animal model of
MS, a close correlation was found between perivascular
fibrin deposition and relapses and, moreover, pathology
was ameliorated after administration of anti-coagulants
or fibrinogen depletion [9,10]. * Correspondence: rainer.ehling@i-med.ac.at
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any medium, provided the original work is properly cited.The aim of this study was to determine the value of fibri-
nogen as biomarker in plasma and CSF of patients with
MS compared to other neurological diseases, and to ana-
lyze potential clinical and neuroradiological correlations.
Methods
Patients
A total of 103 patients were recruited between 2004 and
2009 at the Clinical Department of Neurology,
Innsbruck Medical University, Austria, with approval of
the local ethical committee (study Nr. UN2045, 217/
4.12). All patients gave written informed consent and
were assigned to the following groups:
1. Clinically definite MS patients (n = 40), 27 with
relapsing-remitting (RR) and 13 with chronic pro-
gressive (CP) disease course. Acute relapse was pre-
sent at time of CSF analysis in 30% of MS patients.
All MS patients were examined by a standardized
brain MRI protocol including Gadolinium-DTPA
and scanned using a 1.5 T MR scanner (Magnetom
Avanto, Siemens, Germany) at the time of diagnostic
lumbar puncture, again prior to the application of
methylprednisolone.
2. Patients with BM (n = 15).
3. Patients with viral meningoencephalitis (VM, n =
14). These two groups (2 and 3) were included as
controls, reflecting an acute inflammatory CNS dis-
ease. The neurological outcome of these patients
was evaluated at discharge from clinics by chart
review using the Glasgow Outcome Scale (GOS)
[11,12].
4. Patients with GBS (n = 14) comprised a group
with acute inflammatory disease of the peripheral
n e r v o u ss y s t e m( P N S ) .A l lG B Sp a t i e n t sw e r e
assessed using standard nerve conduction studies
within 6.2 ± 7.7 (mean ± STD) days after disease
onset and classified according to common criteria
[13] into demyelinating (60%), axonal (26.7%) and
normal (13.3%). Disabilities at nadir were scored
from 1-5 according to the Hughes Functional Grad-
ing Scale (HGS) [14].
5. Patients with other, non-inflammatory neurologi-
cal diseases (OND, n = 20) consisted of patients
with chronic back pain (n = 6), chronic headache (n
= 5), ischemic transverse myelopathy (n = 4) and
Bell’s palsy (n = 5). To exclude any biasing inflam-
matory conditions, patients with OND were only
included if they had a normal CSF evaluation.
Sample collection and analysis
Plasma, serum and CSF samples were obtained during
standard diagnostic lumbar and peripheral vein
puncture, and immediately analyzed for CSF white cell
count (WCC), CSF/serum glucose ratio (GluR), CSF/
serum albumin quotient (Qalb), IgG index, total protein
levels, plasma fibrinogen and serum C-reactive protein
(CRP) levels using standard methods: photometric mea-
surement for GluR and total CSF protein, nephelometric
measurement for serum and CSF IgG, ELISA for plasma
fibrinogen and immunturbidimetric measurement for
CRP [15]. CSF fibrinogen was analyzed at a dilution of
1:51 using commercially available ELISA according to
manufacturer’s protocol (RK024A, Hyphen Biomed,
France). Fibrinogen quotient was calculated using the
formula: CSF fibrinogen/plasma fibrinogen. To discrimi-
nate between a passive transfer of fibrinogen through
the blood-CSF barrier (BCSFB) and intrathecal fibrino-
gen production, we calculated an index using the for-
mula: (CSF fibrinogen/plasma fibrinogen)/Qalb. CSF
specimens exceeding a red blood cell count of 33/μl
were excluded to avoid fibrinogen contamination due to
fibrinolysis. All samples were collected prior to the
application of anti-infective, corticosteroid or other
immunomodulatory or immunosuppressive treatment.
Data analysis
Patient characteristics were compared between diagnos-
tic groups by Kruskal-Wallis test or chi-square test
when appropriate. Spearman’sr h ow a sc a l c u l a t e da n d
rho > 0.4 was considered as a relevant correlation. GOS
at hospital discharge of patients with BM and VM were
grouped into favorable (GOS = 5) and unfavorable out-
come (GOS < 5). Disabilities of GBS patients at the
nadir were scored according to the HGS and dichoto-
mized into two groups (< 4 and > = 4). CSF data were
compared between groups by Kruskal-Wallis test, post-
hoc analysis was done by Dunn’s Multiple Comparison
Test. Calculations were done using PASW 18 (IBM,
Chicago, IL, USA), and GraphPad Prism 5.00 (GraphPad
Software, San Diego, CA, USA).
Results
Groups differed significantly in age and sex with an
older age and female predominance in the GBS group
(Table 1). As expected, patients with acute inflammatory
disease of the CNS (BM and VM) had significantly ele-
vated CSF WCC and elevated protein levels. Addition-
ally, the group with BM had a significantly reduced
GluR. The MS cohort had pathologically raised intrathe-
cal immunoglobulin production of the IgG subtype and
97.5% had CSF-specific oligoclonal IgG bands (Table 1).
Cerebral MRI showed significantly more contrast enhan-
cing lesions (CEL) in RR-MS patients as compared to
patients with CP-MS (2.6 ± 6.2 versus 0.5 ± 0.8, number
of CEL, mean ± STD, p < 0.001), but significantly less
T2 hyperintense lesions (26.9 ± 25.9 versus 46.5 ± 27.3,
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0.001).
MS patients had significantly lower fibrinogen levels in
CSF and plasma compared to patients with BM (both p
< 0.001), VM (p <0 . 0 0 1 ,p < 0.01) and GBS (both p <
0.01). Additionally, OND patients had lower fibrinogen
levels in CSF and plasma compared to patients with BM
(p < 0.01; p < 0.05, respectively; Figure 1A and 1B).
The fibrinogen quotient in MS patients was signifi-
cantly lower than in patients with BM and VM (both p
< 0.001; Figure 1C). Qalb was significantly lower in MS
than in BM or VM (both p < 0.001) and also lower than
in GBS (p < 0.05), whereas there was no difference to
OND (Figure 1D). Using data for all patients, Qalb was
significantly correlated to the fibrinogen quotient (rho =
0.769, p < 0.001, Figure 1E). The fibrinogen index,
which was calculated in order to discriminate between a
passive transfer of fibrinogen through the BCSFB and
intrathecal production of fibrinogen, showed a non-sig-
nificant trend towards a lower index in patients with
BM when compared to patients with VM and patients
with OND. However, the overall statistical significance
between groups was p < 0.012 (Figure 1F).
Significant correlations were found between serum
CRP and CSF fibrinogen (rho = 0.483, p <0 . 0 0 1 )a n d
plasma fibrinogen (rho = 0.738, p < 0.001; data not
shown). Fibrinogen was independent of age for all inves-
tigated groups. Fibrinogen levels did not differ for differ-
ent clinical disease courses or during acute relapses in
MS patients when compared to times of remission or
c h r o n i cp r o g r e s s i o n .F u r t h e r m o r e ,C S F ,p l a s m af i b r i n o -
gen and fibrinogen quotient were independent of the
number of T2-hyperintense lesions and the number of
CEL on cerebral MRI scans. Patients with BM and VM
did not differ in clinical outcome using GOS with
respect to their fibrinogen levels. In the GBS group, the
fibrinogen status was independent of the
electrophysiological form of the disease and the severity
of the disease at nadir (data not shown).
Discussion
This study was designed to investigate a possible invol-
vement of CSF fibrinogen in MS pathogenesis during
times of acute inflammation, since vascular abnormal-
ities and accumulation of perivascular fibrin are key
findings in MS [8]. Thus, the finding of normal fibrino-
g e nv a l u e si nC S Fa n dp l a s m ao fM Sp a t i e n t si no u r
study was unexpected. A possible explanation for this
observation could be a restriction of blood-brain barrier
(BBB) breakdown to local areas of acute inflammatory
demyelination as opposed to a diffuse and widespread
BBB breakdown in infectious meningoencephalitis.
Although BBB breakdown in active MS plaques enables
the deposition of fibrinogen, it is not necessarily asso-
ciated with a more permeable BCSFB, thereby prevent-
ing a detectable increase of fibrinogen in the CSF
compartment [16]. Restricted and focal damage of the
BBB in MS may also account for the absence of elevated
CSF fibrinogen levels during acute relapses and the lack
of correlation to CEL. The high molecular weight of
fibrinogen as compared to the lower molecular weight
marker gadolinium used for imaging studies may be an
additional negative confounder.
However, our study found highly increased fibrinogen
levels in the acute inflammatory conditions that are
associated with a diffuse alteration in the state of the
BCSFB, where it is a highly sensitive marker for measur-
ing acute neuroinflammation. The subsequent altering
of the extracellular matrix of the brain parenchyma by
fibrinogen has been shown to inhibit neuroregeneration
and potentiate inflammation in experimental animal
models [9,17]. The finding of elevated CSF fibrinogen
holds not only true for the CNS, but also for an acute
inflammatory condition of the PNS. The finding of
Table 1 Characteristics for patients in the five groups studied
BM VM MS GBS OND p-value
n1 5 1 4 4 0 1 4 2 0
mean age in years (STD) 46.2 (17.0) 41.7 (16.3) 41.2 (11.4) 60.3 (18.1) 39.9 (12.5) 0.012
females (%) 5 (33.3) 6 (42.9) 27 (67.5) 2 (14.3) 11 (55.0) 0.007
CSF WCC/μl (mean, STD) 1612.3 (2042.0) 170.8 (124.0) 9.0 (9.1) 6.1 (6.4) 1.9 (1.7) < 0.001
IgG-index (mean, STD) 0.7 (0.1) 0.5 (0.1) 1.2 (0.7) 0.5 (0.1) 0.5 (0.2) < 0.001
oligoclonal IgG bands (%) nd nd 97.5 nd nd
Qalb (mean, STD) 50.8 (40.8) 17.7 (8.5) 5.6 (2.5) 13.1 (9.2) 6.7 (3.6) < 0.001
CSF/serum glucose ratio (mean, STD) 0.3 (0.2) 0.7 (0.2) 0.7 (0.2) 0.8 (0.4) 0.7 (0.1) < 0.001
protein (mg/dl, mean, STD) 354.9 (383.8) 116.2 (44.3) 43.0 (15.1) 76.1 (51.7) 38.4 (10.7) < 0.001
CRP serum (mg/dl, mean, STD) 12.5 (11.2) 0.9 (1.4) 0.3 (0.7) 2.0 (3.8) 0.4 (0.5) < 0.001
BM, bacterial meningitis; VM, viral meningoencephalitis; MS, multiple sclerosis; GBS, Guillain-Barré syndrome; OND, other non-inflammatory neurological diseases;
STD, standard deviation; CSF, cerebrospinal fluid; WCC, white cell count; Qalb, CSF/serum albumin quotient.
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Page 3 of 5Figure 1 Data plots of fibrinogen concentration in the five investigated patient groups. A: fibrinogen in CSF, B: fibrinogen in plasma. MS
patients had significantly lower fibrinogen levels in CSF and plasma as compared to patients with BM, VM and GBS. In addition, OND patients
had lower fibrinogen levels in CSF and plasma as compared to patients with BM (bar = mean, * p < 0.05, ** p < 0.01, *** p < 0.001). C: Data
plots of fibrinogen quotient (CSF/serum) for the five patient groups, showing significantly lower values in patients with MS as compared to
patients with BM and VM (bar = mean, *** p < 0.001). D: Data plots of albumin quotient (Qalb) for the five patient groups. Patients suffering
from MS had a significantly lower Qalb compared to those with acute inflammatory diseases of the CNS (BM and VM) reflecting an altered
BCSFB status. Qalb was also significantly lower in patients with MS as compared to patients with GBS, reflecting, in this context, an altered brain-
nerve barrier status in GBS. However, Qalb did not differ between MS and OND patients (bar = mean, * p < 0.05, *** p < 0.001). E: Scatter plot of
albumin quotient against fibrinogen quotient for all patients. Qalb was significantly correlated to fibrinogen quotient (rho = 0.769, p < 0.001). F:
Data plot of the fibrinogen index [(CSF fibrinogen/plasma fibrinogen)/Qalb] for the five patient groups. The overall statistical significance
between groups was p < 0.012; at the group level there was a non-significant trend towards lower values in patients with BM as compared to
patients with VM and patients with OND.
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previous studies [6] and of particular interest since the
impairment of the blood-nerve barrier in this context is
irrespective of an infectious agent.
Due to the relatively small number of patients investi-
gated and the retrospective design, our study was not
powered to detect other influencing factors on the
plasma fibrinogen status [3] and the conclusions may
therefore be limited. However, our study has demon-
strated elevated levels of CSF fibrinogen in patients with
acute inflammatory diseases of the CNS and the PNS,
where to our best knowledge influencing factors have
not been thoroughly investigated. In these acute inflam-
matory disorders fibrinogen may enter the CSF directly
through the BCSFB or indirectly through the BBB and
make an important contribution to inflammatory and
regenerative processes. In contrast, CSF fibrinogen is
not increased in MS patients, where an apparently intact
BCSFB prevents fibrinogen entering the CSF. This fea-
ture may be useful to distinguish MS from acute CNS
inflammatory diseases.
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